Abstract
Magnetic resonance imaging (MRI) provides an objective method of evaluating multiple sclerosis clinical trials and is at least five times more sensitive to disease activity. In a recent clinical trial, MRI was also approximately twice as sensitive as clinical measurements to the treatment effect of a drug.
MeSH terms
-
Brain / pathology*
-
Clinical Trials as Topic / methods
-
Clinical Trials as Topic / standards*
-
Cyclosporine / therapeutic use
-
Humans
-
Interferon-alpha / therapeutic use
-
Interferon-beta / therapeutic use
-
Magnetic Resonance Imaging* / standards
-
Magnetic Resonance Imaging* / statistics & numerical data
-
Multiple Sclerosis / diagnosis
-
Multiple Sclerosis / drug therapy
-
Multiple Sclerosis / pathology*
-
Placebos
-
Sensitivity and Specificity
-
Severity of Illness Index
Substances
-
Interferon-alpha
-
Placebos
-
Interferon-beta
-
Cyclosporine